Feb 29 |
Arcellx, Inc. (ACLX) Q4 Earnings and Revenues Surpass Estimates
|
Feb 28 |
Arcellx reports Q4 results
|
Feb 28 |
Arcellx Provides Fourth Quarter and Year-End 2023 Financial Results and Business Highlights
|
Feb 15 |
The 3 Biotech Stocks That Could Make Your February Unforgettable
|
Feb 1 |
Arcellx, Inc. (NASDAQ:ACLX) Shares Could Be 40% Below Their Intrinsic Value Estimate
|
Jan 30 |
Arcellx: Navigating The CAR T-Cell Revolution
|
Jan 16 |
Healthcare Heroes: 3 Biotech Stocks Poised to Cure What Ails the Market
|
Dec 22 |
Chief Medical Officer Christopher Heery Sells 120,000 Shares of Arcellx Inc
|
Dec 15 |
Pharma’s Frontline: 3 Stocks Driving Revolutionary Drug Development
|
Dec 8 |
Arcellx Announces Continued Robust Long-Term Responses from Its CART-ddBCMA (anito-cel) Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma at ASH
|